ArticleThe Lancet regional health. Western Pacific2023

(5R)-5-hydroxytriptolide for HIV immunological non-responders receiving ART: a randomized, double-blinded, placebo-controlled phase II study.

Wei Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.